An interventional study of Probiotic and Placebo in ALSFTD, ALS (Amyotrophic Lateral Sclerosis) and Frontal Temporal Dementia (FTD), sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 24th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 7 with no phase, reaches primary completion later than 8 of the 24 other live ones, and was the 65th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Nura Bio · Sites in Canada, Australia, Netherlands and 1 more country
Ages 18–80
Prilenia · Sites in Canada, United States, Belgium and 10 more countries
Ages 18–80
Zydus Therapeutics Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 29 · Phase 3 23 · Phase 4 1
First in 2001; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 75 across the 72 interventional studies, 148 across the 10 observational. Of the 49 that completed or were terminated, 24 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 82 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07193953Sunnybrook Health Sciences CentreIntravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-30 |
| NCT06051123Centre hospitalier de l'Université de Montréal (CHUM)Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants receiving the placebo at different time points.
Individuals with ALS-FTDSD, their caregivers and healthy individuals can participate in this randomized, double-blind, parallel, placebo-controlled study. Participants will be enrolled for a period of 32 weeks, with an intervention period of 24 weeks. For ALS-FTDSD participants, there will be 9 visits during the intervention (5 in-person and 4 phone calls) and 1 follow-up call post-intervention. For healthy participants, there will be 4 in-person visits. For all participants, in-person visits will involve filling out questionnaires, giving blood samples, and returning stool samples.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following inclusion criteria to be eligible for enrolment into the study:ALS-FTDSD participants
Participants of must have a negative serum pregnancy test at screening and agree to use a medically approved method of for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Healthy controls:
Participants of child-bearing potential must have a negative serum pregnancy test at screening and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
Informant/caregiver
Exclusion criteria:
Subjects with any of the following characteristics/conditions will not be included in the study:
ALS-FTDSD participants
Healthy controls:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will be randomized to receive a probiotic formulation for 24 weeks.
Dietary Supplement: Probiotic
Participants in this group will be randomized to receive a placebo for 24 weeks.
Dietary Supplement: Placebo
Participants will be taking 1 sachet a day.
Participants will be taking 1 sachet a day.
Change in lipids and polar metabolites composition in the plasma of participant
Metabolomics will provide a quantitative and qualitative assesment of the lipidomic and polar metabolite profiles of participants on the probiotic arm and the participants on the placebo arm. Participants will be assessed at week 0, at week 12 and then at the end of the investigation period at week 24.
Time frame: 24 weeks
Change in ALS Functional Rating Scale Revised (ALSFRS-R) score
Participants' ALS Functional Rating Scale Revised (ALSFRS-R) score, following intake of the probiotic or placebo. Participants will be assessed at week 0, at week12 and then at the end of the investigation period at week 24.
Time frame: 24 weeks
Change in ALS-CBS score
To compare the average change from baseline in ALS Cognitive Behavioral Screen (ALS-CBS) and Frontal Assessment Battery (FAB) between the probiotic and placebo groups over the 24 weeks of intervention.
Time frame: 24 weeks
Change in neurofilament light chain concentration
To compare the average change from baseline in the neurofilament light chain concentration between the probiotic and placebo groups over the 24 weeks of intervention.
Time frame: 24 weeks
Change in ALSAQ-5 scores
To compare the average change from baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire-5 (ALSAQ-5) between the probiotic and placebo groups over the 24 weeks of intervention.
Time frame: 24 weeks
Change in fecal microbiota in ALS-FTDSD patients
To compare the fecal microbiota composition, diversity, and strain recovery over the 24 weeks of intervention in the probiotic and placebo groups. Techniques will be based on the extraction of DNA and amplification of 16S ribosomal RNA genes. These genes are highly conserved between bacterial species, but vary in a manner that allows species identification.
Time frame: 24 weeks
Lipidomic profiles of healthy participants
To explore lipidomic profiles from baseline in healthy participants over the 24 weeks of intervention. This will be a lipid profiling and quantification by using mass-spectrometry-based lipidomics. We are going to test 900 different lipids, which can be classified in 20 classes ans subclasses of interest.
Time frame: 24 weeks
Number of AEs and SAEs
To compare the number of adverse events (AEs) and serious adverse events (SAEs) that occur among to the probiotic group versus the placebo group throughout the study.
Time frame: 28 weeks
Changes in lab safety marker: Complete Blood Count (CBC)
Changes (outside normal variation) in safety lab marker: Complete Blood Count (CBC).
Time frame: 24 weeks
Changes in lab safety markers: Liver Function Test (LFT) - ALT
Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely alanine transaminase (ALT).
Time frame: 24 weeks
Changes in lab safety markers: Liver Function Test (LFT) - AST
Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely aspartate transaminase (AST).
Time frame: 24 weeks
Changes in lab safety markers: Liver Function Test (LFT) - bilirubin
Changes (outside normal variation) in safety lab markers :Liver Function Tests (LFTs), more precisely total bilirubin.
Time frame: 24 weeks
Changes in lab safety marker: creatinine
Changes (outside normal variation) in safety lab marker: creatinine.
Time frame: 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Feb 2027, 37 months after the start.
Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 37 months is close to that.
Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
Amyotrophic Lateral Sclerosis →
Centre hospitalier de l'Université de Montréal (CHUM) →